Left ventricular hypertrophy: reduction of blood pressure already in the normal range further regresses left ventricular mass

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN48331653

Enrollment

Registered

2006-03-29

Start date

2005-03-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left ventricular hypertrophy Circulatory System Left ventricular hypertrophy

Interventions

Two thirds of patients to receive active medication (normal antihypertensives once daily including: bendroflumethiazide 2.5 mg, amlodipine 5 mg, atenolol 50 mg, doxazosin XL 4 mg, spironolactone 25 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Normal blood pressure 2. Left ventricular hypertrophy 3. On angiotensin converting enzyme (ACE) inhibitor or angiotensin II (AII) receptor blocker or contraindication to both

Exclusion criteria

Exclusion criteria: 1. Renal disease 2. Proteinuria 3. Claustrophobia or other contraindication to magnetic resonance imaging (MRI) scanning

Design outcomes

Primary

Measure	Time frame
Assess for reduction in left ventricular mass index as calculated from MRI	—

Secondary

Measure	Time frame
Reduction in other markers of cardiovascular risk	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 2, 2026